(Q39038413)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Federica Pisa

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

6

Elena Masiero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Luisa Foltran

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Giovanna De Maglio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Nicoletta Pella

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Paola Ermacora

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Giuseppe Aprile

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Mariella Giovannoni

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Emiliana Iaiza

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Giovanni Gerardo Cardellino

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Stefania Eufemia Lutrino

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Micol Mazzer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Stefano Pizzolitto

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Gianpiero Fasola

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

629-640

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25686118%20AND%20SRC:MED&resulttype=core&format=json

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Recurrent KRAS codon 146 mutations in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

The relationship between tumour site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

The impact of comorbidity on cancer survival: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279

Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.279